Clinical Research Directory

Inclusion Criteria: * Be over 18 years old * Be HIV-1 antibody positive as determined by a positive 4th generation Ag/Ab ELISA assay * Be stable on ART with a viral load suppressed \<40 copies/mL for a minimum of 2 years * Have a CD4 count ≥200 cells/mm3 for a minimum of 1 year * Have a BMI ≥30kg/m2 or have a BMI ≥27kg/m2 and hypertension, dyslipidaemia or type 2 diabetes mellitus * Understand the study procedures, be able to comply with the study procedures, and voluntarily agree to participate by giving written informed consent for the trial Exclusion Criteria: * Subjects unable to comply with the study protocol or unable to self-administer subcutaneous semaglutide * History of obesity induced by other endocrine disorders: hypothyroidism, Cushing's syndrome, primary and secondary hypogonadism, hypothalamic disorders, polycystic ovary syndrome, insulinoma * History of obesity induced by use of anti-psychotic medications known to be associated with weight gain (i.e. olanzapine, clozapine). * Treatment with GLP-1 receptor agonists (including liraglutide, semaglutide or exenatide), dipeptidyl peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months (including saxagliptin, linagliptin, sitagliptin) * History of severe renal impairment, as defined by a baseline creatinine clearance \<30ml/min * Individuals with a diagnosis of HIV-associated lipoatrophy/lipodystrophy, based on physician's assessment * Individuals with severe hepatic impairment (Child Pugh score \>9) * Subjects with active hepatitis B infection (defined as hepatitis B sAg positive) or hepatitis C (defined as hepatitis C Ab and RNA positive) co-infection * Any active illness (including AIDS-defining illness) which in the opinion of the investigator precludes participation in the study * History of cancer (apart from treated Kaposi's Sarcoma) and/or receiving chemotherapy or radiotherapy * Active illicit intravenous drug use * Subjects concurrently enrolled in another clinical trial of an investigational medicinal product. * The investigator may decide that a subject cannot proceed in the study if there is any relevant other abnormal results in the screening assessments * Subjects with any known or suspected hypersensitivity to semaglutide or any of the excipients of semaglutide * Subjects on another medicinal product prescribed primarily for weight loss e.g. orlistat (see prohibited/cautioned concomitant medications/therapies section) * For female subjects: pregnancy or breastfeeding at screening, planning future pregnancies or unwilling to take measures to avoid pregnancy for the duration of the study